The AHA, American Society of Health-System Pharmacists, American Society of Anesthesiologists, Institute for Safe Medication Practices, and American Society of Clinical Oncology today urged the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve. “We understand and share the DEA’s concern that these medications need to be well‐managed and used judiciously to help stem the nation’s opioid epidemic,” the organizations wrote. “We fully support and use advances in pain management, such as multimodal analgesia, that enable patients to undergo procedures with fewer opioids and less reliance on opioids after surgery. Nonetheless, injectable opioids remain a crucial component of patient management during and immediately after many operations. With no appropriate opioids available, operations would have to be postponed or cancelled. In some cases, this could prove life‐threatening to the patient.”

Related News Articles

Drug overdose deaths declined 5.1% in 2018 to about 68,000, according to preliminary data from the Centers for Disease Control and Prevention.
The House Ways and Means Committee today launched a health task force to better address the needs of residents in rural and underserved communities.
Under a new Centers for Medicare…
In this AHA Stat Blog, Jay Bhatt, senior vice president and chief medical officer of the AHA, looks at last year’s Innovation Challenge winners and how they…
The AHA and the Department of Homeland Security July 17 at 1 p.m. ET will host a webinar discussing current cybersecurity threats to the health care sector.
Chairperson's File
Hospitals and health systems are tackling affordability head on. AHA’s The Value Initiative has been leading the charge — developing new resources, sharing…